| Authors: |
Masri A; Division of Cardiovascular Medicine, Oregon Health and Sciences University, Portland (A.M.)., Cappelli F; Tuscan Regional Amyloidosis Center, Department of Clinical and Experimental Medicine, University Hospital Careggi, Florence, Italy (F.C.)., Davis MK; Division of Cardiology, University of British Columbia, Vancouver, Canada (M.K.D.)., Fontana M; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, United Kingdom (M.F., J.D.G.)., Garcia-Pavia P; Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV and Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain (P.G.-P.)., Gillmore JD; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, United Kingdom (M.F., J.D.G.)., Hanna M; Department of Cardiovascular Medicine, Cleveland Clinic, OH (M.H.)., Obici L; Amyloidosis Research and Treatment Centre, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy (L.O.)., Solomon SD; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (S.D.S.)., Sperry BW; Saint Luke's Mid America Heart Institute, Kansas City, MO (B.W.S.)., Tahara N; Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Japan (N.T.)., Waddington-Cruz M; Centro de Paramiloidose Antônio Rodrigues de Mello (CEPARM), Amyloidosis Center, University Hospital, Federal University of Rio de Janeiro, Brazil (M.W.-C.).; Amyloidosis Center, Complexo Hospitalar Américas-Samaritano-Vitória, Rio de Janeiro, Brazil (M.W.-C.)., Kristen AV; Amyloidosis Center, University of Heidelberg, Germany (A.V.K.).; Cardiovascular Center Darmstadt, Germany (A.V.K.)., Falk RH; Harvard Medical School and Brigham and Women's Hospital, Boston, MA (R.H.F.)., Shah SJ; Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.)., Nativi-Nicolau J; Mayo Clinic, Jacksonville, FL (J.N.-N.)., Viney NJ; Ionis Pharmaceuticals, Inc., Carlsbad, CA (N.J.V., Q.Y., S.T.)., Yang Q; Ionis Pharmaceuticals, Inc., Carlsbad, CA (N.J.V., Q.Y., S.T.)., Chen J; Late-Stage Clinical Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MA (J.C.)., Tsimikas S; Ionis Pharmaceuticals, Inc., Carlsbad, CA (N.J.V., Q.Y., S.T.)., Maurer MS; Columbia University Irving Medical Center, New York, NY (M.S.M.). |
